Skip to main content
Premium Trial:

Request an Annual Quote

Consortium Wins $11.7M Grant from European Commission to Uncover Biomarkers for MI

NEW YORK, Feb. 3 (GenomeWeb News) - The European Commission's Sixth Research Framework Programme has provided a four-year, €9 million ($11.7 million) grant to a research consortium that hopes to discover genetic markers associated with a risk of myocardial infarction and clot formation, according to the University of Cambridge.

 

The 14 memebrs of the consortium, called "Bloodomics," have set up the European Cardiovascular Genetics Foundation to manage the project, according to the school. Bloodomics will include researchers from the Universityof Cambridgein the UK; Domantis, a UK-based antibody company; Trium Analysis Online, a German informatics company; and the national blood services of the UKand The Netherlands. At least 180 investigators will work as part of Bloodomics.

 

Research will focus initially on the genes and proteins controlling platelets, with the eventual goal of producing new drugs for the prevention and treatment of heart disease.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.